Search clinical trials for: glargine

Total 612 results

Sanofi

Completed

Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes (AFICIONADO)

Diabetes Mellitus, Type 2

Argentina
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus (EDITION JP I)

Type 1 Diabetes Mellitus

Japan
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus (EDITION JP II)

Type 2 Diabetes Mellitus

Japan
Chung-Ang University Hosptial, Chung-Ang University...

Completed

Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia

Deep Extubation

Korea, Republic of
Institut de Recherches Cliniques de Montreal
Novo Nordisk A/S; McMaster University

Completed

Levemir-Body Composition and Energy Metabolism

Type 2 Diabetes

Canada
Eli Lilly and Company

Completed

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes (AUTONOMY)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Poland, Canada, Austria, Mexico, Denmark, Croatia, Brazil, Argentina, Romania, South Africa, Russian Federation, France, Lithuania
Sanofi

Completed

Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure (EAGLE)

Diabetes Mellitus, Type 2

Brazil, United States, Finland, Spain, Austria, Canada, Czech Republic, France, Greece, Ireland, Israel, Mexico, Netherlands, Russian Federation, Slovakia, Sweden, Turkey
Daiichi Sankyo, Inc.

Completed

Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Sanofi

Completed

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old. (Lantus-P-CN)

Type 1 Diabetes Mellitus

China
Sanofi

Completed

baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus (SUBSTITUTE)

Diabetes Mellitus, Type 1

Tunisia, South Africa, Algeria, Argentina, Brazil, Colombia, Kuwait, Mexico, Saudi Arabia
Emory University
Sanofi

Completed

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery (RABBIT 2-SX)

Type 2 Diabetes | Inpatient Hyperglycemia

United States
Eli Lilly and Company

Completed

Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies

Diabetes Mellitus, Type 2

Turkey, Argentina, Korea, Republic of, Brazil, China, Egypt, India, Spain
Eli Lilly and Company

Completed

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Taiwan, China, Korea, Republic of
Emory University
Sanofi; University of Miami

Completed

Basal/Bolus Versus Sliding Scale Insulin In Hospitalized Patients With Type 2 Diabetes

Hyperglycemia | Diabetes

United States
Sanofi

Completed

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (DINAMO)

Diabetes Mellitus, Type 2

Brazil
University of Alberta
Sanofi

Completed

Pharmacist Intervention for Glycemic Control in The Community (RxING)

Type 2 Diabetes

Canada
Medical University of South Carolina

Completed

IV Insulin Protocol in Diabetes and Renal Transplantation

Hyperglycemia | Diabetes | Kidney Transplantation

United States
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Sanofi

Withdrawn

Intensive Glycemic Control on Infectious Morbidity In Patients With Acute Leukemia

Hyperglycemia | Leukemia

United States
Sanofi

Completed

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Sanofi

Completed

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Type1 Diabetes

Germany
Sanofi

Completed

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus (Pen Preference)

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes

Healthy | Diabetes | Diabetes Mellitus, Type 1

Germany
Sanofi

Completed

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Diabetes Mellitus, Type 2

Korea, Republic of
Sanofi

Completed

Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus (ATLAS)

Diabetes Mellitus, Type 2

Japan, Russian Federation, China, India, Pakistan, Philippines
Sanofi

Terminated

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (BASAAL PLUS)

Diabetes Mellitus, Type 2

Netherlands
Tehran University of Medical Sciences

Completed

Cost Effectiveness of Glargine Insulin Versus NPH Insulin

Type 2 Diabetes Mellitus

Iran, Islamic Republic of
Sanofi

Completed

Insulins Glargine and gluLisine strAtegy Versus Premixed Insulin strAteGy: a cOmparative Study (GALAPAGOS)

Diabetes Mellitus, Type 2

Austria, United Arab Emirates, Spain, Romania, Colombia, Korea, Republic of, Brazil, Greece, Italy, China, Denmark, India, Kuwait, Mexico, Taiwan, Turkey
Handok Inc.

Completed

Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Korea, Republic of
The Coca-Cola Company

Completed

Evaluation of a New Orange-Based Beverage Enriched With Polyphenols in Adult Humans (BIONAOS)

Obesity | Overweight

Spain
Oregon Health and Science University
Eli Lilly and Company; Amylin Pharmaceuticals, LLC.

Completed

How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics (MEXELIN)

Type 2 Diabetes

United States
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Chongqing Medical University

Completed

Comparison of Glargine and Oral Antidiabetic Drugs (OADs) in Newly Diagnosed Type 2 Diabetes

Diabetes

China
Sanofi
Population Health Research Institute

Completed

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN)

Diabetes Mellitus, Non-Insulin-Dependent

United States, France, Brazil, Poland, Romania, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, India, Philippines, Russian Federation, Slovakia, Mexico, Argentina, Croatia, Austria, Denmark, Finland, Hungary, Lithuania, Norw... and more
Sanofi

Completed

Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (GAUDI)

Type 2 Diabetes Mellitus

Japan
Wockhardt

Completed

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

Type1 Diabetes

United States
Sanofi

Completed

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients (LanScape)

Diabetes Mellitus, Type 2

Australia, United Kingdom
Sanofi

Completed

Apidra Children & Adolescents Study

Diabetes Mellitus, Type 1

Russian Federation
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Tamra Dukatz
Sanofi

Completed

Perioperative Insulin Glargine Dosing Study

Diabetes | Surgery

United States
Sanofi

Completed

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Eli Lilly and Company

Terminated

Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (HMH)

Hyperglycemia

United States
University Hospital Tuebingen
Medical University of Vienna; University of Bern; CenTrial GmbH

Terminated

Weight Gain, Eating Patterns, and Development of Body Composition During Initiation of Basal Insulin Therapy in Patients With Type 2 Diabetes: A Comparison of Insulin Detemir and Insulin Glargine

Obesity | Diabetes

Austria, Germany, Switzerland
Sanofi

Completed

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
Sanofi

Completed

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients (EASIE)

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, Turkey, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
Sanofi

Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs (CHANGING)

Diabetes Mellitus, Type 2

Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela
Sanofi

Completed

Lantus Versus NPH: Comparison in Insulin Naive People Not Adequately Controlled With at Least One Oral Anti Diabetics (OAD) Treatment (LANCELOT)

Diabetes Mellitus, Type 2

Brazil, Thailand, Slovakia, Poland, Netherlands, Kuwait, Mexico, Korea, Republic of, Czech Republic, Egypt, France, Italy, Romania, Russian Federation, Sweden, Switzerland, United Arab Emirates
Sanofi

Completed

Insulin Glargine (Lantus) vs Sulfonylurea (SU) for BETA Cell Function (BETA Study)

Type 2 Diabetes Mellitus

Korea, Republic of
Sanofi

Completed

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

Diabetes Mellitus, Type 1

Belarus
Sanofi

Completed

6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes (PRESCHOOL)

Type 1 Diabetes Mellitus

United States, Austria, Brazil, Chile, Czech Republic, Germany, Hungary, India, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Turkey

3

Subscribe